Interface Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 results with net sales up 5.4% and adjusted EPS up 33%, driven by strong healthcare and education growth, margin expansion from automation, and new product launches. 2026 guidance anticipates continued growth, robust backlog, and increased capital investment.
-
Q3 2025 saw 4% currency-neutral net sales growth and 208 bps margin expansion, led by strong healthcare and nora rubber performance. Full-year guidance was raised, with continued investments in automation and innovation supporting future growth.
-
Q2 2025 saw 7% currency-neutral net sales growth and 50% higher adjusted EPS, driven by strong Americas performance, margin expansion, and broad-based segment growth. Full-year guidance was raised, with automation and sustainability initiatives supporting future gains.
-
Q1 2025 saw 4% currency-neutral net sales growth and 4% adjusted EPS growth, with strong performance in education, healthcare, and APAC. Guidance for 2025 was raised, with tariff impacts expected to be offset by pricing and productivity.
Fiscal Year 2024
-
Delivered 4% net sales growth and nearly doubled GAAP EPS in 2024, led by strong Americas performance and operational efficiencies. Entering 2025 with a robust backlog, margin expansion plans, and disciplined capital allocation, while monitoring macro and FX risks.
-
Q3 2024 saw double-digit sales and margin growth, led by the Americas and strong education, retail, and corporate office segments. Raised full-year guidance reflects robust order momentum, margin expansion, and continued operational investments.
-
Q2 2024 saw 6% year-over-year currency neutral net sales growth and a 183 basis point rise in adjusted gross profit margin, driven by strong performance in the Americas and education segment. Full-year guidance was raised, with continued investment in automation and a robust backlog supporting future growth.